A Randomized Trial to Assess the Role of Imaging During Follow Up After Radical Surgery of High Risk Melanoma
Key facts
- Where
- Borås, Eskilstuna, Falun, Gävle, Gothenburg, Helsingborg, Jönköping, Kalmar, Karlstad, Linköping, Malmö, Örebro, Skövde, Stockholm, Sundsvall, Uddevalla, Umeå, Uppsala, Västerås, and Visby, SwedenSee the 20 sites
Where in Sweden
- Södra Älvsborgs SjukhusBorås, SwedenNo longer taking part
- Malarsjukhuset EskilstunaEskilstuna, SwedenTaking people
- Falu LasarettFalun, SwedenTaking people
- Gävle sjukhusGävle, SwedenTaking people
- Department of Surgery, Sahlgrenska University HospitalGothenburg, SwedenTaking people
- Helsingborgs lasarettHelsingborg, SwedenTaking people
- Lanssjukhuset RyhovJönköping, SwedenTaking people
- Länssjukhuset i KalmarKalmar, SwedenNot yet recruiting
- Centralsjukhuset i KarlstadKarlstad, SwedenTaking people
- Linkoping University HospitalLinköping, SwedenTaking people
- Skåne University HospitalMalmö, SwedenTaking people
- Örebro University HospitalÖrebro, SwedenTaking people
- Skaraborgs sjukhus SkövdeSkövde, SwedenNo longer taking part
- Karolinska University HospitalStockholm, SwedenTaking people
- Länssjukhuset SundsvallSundsvall, SwedenTaking people
- Uddevalla sjukhusUddevalla, SwedenNo longer taking part
- Umeå University HospitalUmeå, SwedenNo longer taking part
- Akademiska sjukhusetUppsala, SwedenTaking people
- Västmanlands Sjukhus VästeråsVästerås, SwedenTaking people
- Visby lasarettVisby, SwedenTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Uppsala University
- Trial code
- NCT03116412
- Record updated
- 16 December 2024
- Original description
It is not known whether radiological assessments during follow up after surgery for high risk melanoma improve survival. Since radiological examinations are resource demanding, could inflict worry and cause irradiation exposure it is an important question to address. With the introduction of effective medical treatments for malignant melanoma patients, there is a tendency to introduce radiological assessments despite the lack of evidence.Read full original descriptionShow less
A Prospective Randomized Multicenter Trial to Assess the Role of Imaging During Follow Up After Radical Surgery of Stage IIb-c and III Cutaneous Malignant Melanoma
It is not known whether radiological assessments during follow up after surgery for high risk melanoma improve survival. Since radiological examinations are resource demanding, could inflict worry and cause irradiation exposure it is an important question to address. With the introduction of effective medical treatments for malignant melanoma patients, there is a tendency to introduce radiological assessments despite the lack of evidence.
Inclusion: At least 18 years of age; Radical surgery for Cutaneous Malignant Melanoma (CMM) stage IIb-c and III; Sufficient renal function for i.v. contrast scannings.
Exclusion: Life-expectancy less than 2 years due to concurrent disease (e.g., cardiac disease, terminal multiple sclerosis, liver cirrhosis); Existing or previous malignancies within the past 5 years (except for in situ breast and cervical cancer, melanoma in situ and non-melanoma skin cancer); The patient is assessed as unfit to receive treatment in the case of recurrence; Inability to provide informed consent or refusal to do so; Inability to comply with the control or intense follow-up program; Participation in other clinical trials interfering with the control-program; Pregnancy or currently planned pregnancy.